{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:47:37Z","timestamp":1790412457318,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.aed.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:26:04Z","timestamp":1764203164000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tirzepatide-Induced Liver Injury: A Rare Complication"],"prefix":"10.1016","volume":"13","author":[{"given":"Lauren D.","family":"Spaeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah P.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9777-7620","authenticated-orcid":false,"given":"Daryl A.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aed.2025.11.009_bib1","author":"Montero"},{"issue":"11","key":"10.1016\/j.aed.2025.11.009_bib2","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.aed.2025.11.009_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10295","key":"10.1016\/j.aed.2025.11.009_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aed.2025.11.009_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10300","key":"10.1016\/j.aed.2025.11.009_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.aed.2025.11.009_bib7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.aed.2025.11.009_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.aed.2025.11.009_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.aed.2025.11.009_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.aed.2025.11.009_bib11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.aed.2025.11.009_bib12","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.aed.2025.11.009_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.aed.2025.11.009_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","article-title":"Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"61","author":"Urva","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.aed.2025.11.009_bib16","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.cgh.2024.06.025","article-title":"First report of tirzepatide hepatotoxicity with jaundice","volume":"22","author":"Fontana","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.aed.2025.11.009_bib17","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001484","article-title":"A rare case of tirzepatide-induced hepatotoxicity","volume":"11","author":"Sohal","year":"2024","journal-title":"ACG Case Rep J"},{"issue":"9","key":"10.1016\/j.aed.2025.11.009_bib18","article-title":"Tirzepatide-related acute liver injury","volume":"11","author":"Abdullah","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"issue":"4","key":"10.1016\/j.aed.2025.11.009_bib19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.15403\/jgld-5967","article-title":"Idiosyncratic acute liver failure induced by tirzepatide","volume":"33","author":"Terrington","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"10.1016\/j.aed.2025.11.009_bib20","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001661","article-title":"Tirzepatide-induced liver injury: a rare medication side effect","volume":"12","author":"Phox","year":"2025","journal-title":"ACG Case Rep J"},{"issue":"6","key":"10.1016\/j.aed.2025.11.009_bib21","doi-asserted-by":"crossref","first-page":"1383A","DOI":"10.1002\/hep.32218","article-title":"Oral abstracts","volume":"74","author":"Kowdley","year":"2021","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.aed.2025.11.009_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.aed.2025.11.009_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/biomedicines9020106","article-title":"Liraglutide-induced hepatotoxicity","volume":"9","author":"Maor","year":"2021","journal-title":"Biomedicines"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725001857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:28:50Z","timestamp":1777260530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3050915725001857"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.11.009","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide-Induced Liver Injury: A Rare Complication","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association of Clinical Endocrinology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}